ORAL DOSAGE FORMS OF ANTI-AIDS AGENTS

抗艾滋病药物的口服剂型

• 批准号: 3616677
• 负责人: TING-FONG CHIN
• 金额: $ 16.45万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-09-30 至 1994-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3616677
• 关键词: antiAIDS agent; dosage forms; drug administration routes; drug design /synthesis /production

The objective of this resource function is to develop and produce pharmaceutically acceptable dosage forms of promising new agents with anti-AIDS activity. Some agents selected by a Drug Selection Committee at NIH will be assigned for development and manufacture as oral products. Initially, the batch sizes are expected to be small for Phase I and II trials. However, escalation to large batch sizes for Phase III/IV trials and Group C distribution is anticipated. It is estimated that this project must be prepared to produce several million oral dosage units each year.

这种资源功能的目标是开发和生产 有希望的新药剂的药学上可接受的剂型， 抗艾滋病活动。一些药物由药物选择委员会在 NIH将被指定作为口服产品进行开发和生产。 最初，预计I期和II期的批量较小 审判然而，III/IV期试验的批量扩大 预计将进行C组分配。估计这 一个项目必须准备生产数百万个口服剂量单位 每年.